Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency. The company ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Opella Valuation: EUR16 billion EV, 14 times 2024 estimated EBITDA. Sanofi SA (NASDAQ:SNY) reported a strong sales performance with Q3 sales reaching EUR13.4 billion, marking a 16% increase in ...

After missing out on the glucagon-like peptide 1 obesity market, Sanofi SA is prospecting for next-generation drugs and is making a strategic equity investment in Resalis Therapeutics Srl, providing ...

Instead, it risks becoming a political football. Sanofi SA nudged the auction for its consumer health business nearer to consummation on Friday, agreeing exclusive talks to sell a “50% ...

Opella serves over 500M consumers globally with top brands like Allegra and Dulcolax. Sanofi SA SNY and private equity Clayton Dubilier & Rice (CD&R) have finally entered into exclusive ...

The US buyout firm is pairing with the French pharma giant to buy out its consumer unit. Success here requires much more than cutting costs. Chris Hughes is a Bloomberg Opinion columnist covering ...

Opella Valuation: EUR16 billion EV, 14 times 2024 estimated EBITDA. Sanofi SA (NASDAQ:SNY) reported a strong sales performance with Q3 sales reaching EUR13.4 billion, marking a 16% increase in ...